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isclosuThe occurrence of hepatic veno-occlusive disease (VOD) has been reported in up to 60% of patients follow-
ing stem cell transplantation (SCT), with incidence varying widely between studies depending on the type of
transplant, conditioning regimen, and criteria used to make the diagnosis. Severe VOD is characterized by
high mortality and progression to multiorgan failure (MOF); however, there is no consensus on how to eval-
uate severity. This review and analysis of published reports attempts to clarify these issues by calculating the
overall mean incidence of VOD andmortality from severe VOD, examining the effect of changes in SCT prac-
tice on the incidence of VOD over time, and discussing the methods used to evaluate severity. Across 135
studies performed between 1979 and October 2007, the overall mean incidence of VOD was 13.7% (95%
confidence interval [CI]5 13.3%-14.1%). The mean incidence of VOD was significantly lower between
1979-1994 than between 1994-2007 (11.5% [95% CI, 10.9%-12.1%] vs 14.6% [95% CI, 14.0%-15.2%];
P\.05). The mortality rate from severe VOD was 84.3% (95% CI, 79.6%-88.9%); most of these patients
had MOF, which also was the most frequent cause of death. Thus, VOD is less common than early reports
suggested, but the current incidence appears to be relatively stable despite recent advances in SCT, including
the advent of reduced-intensity conditioning. The evolution of MOF in the setting of VOD after SCT can be
considered a reliable indication of severity and a predictor of poor outcome.
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failureINTRODUCTION
Hepatic veno-occlusive disease (VOD) is a syn-
drome characterized by clinical features of rapid
weight gain, ascites, painful hepatomegaly, and jaun-
dice [1]. It is more common after allogeneic stem cell
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Table 1. Clinical Criteria for the Diagnosis of VOD
Original Seattle Criteria [4] Baltimore Criteria [6]
Presence before day 30 post-SCTof 2
or more of the following:
 Bilirubin$ 2 mg /dL (z 34 mmol/L)
 Hepatomegaly, right upper quadrant
pain
 Ascites with or without unexplained
weight gain of >2% over baseline
Bilirubin$ 2 mg/dL before day 21
post-SCT and at least 2 of the
following:
 Hepatomegaly (usually painful)
 Ascites
 Weight gain >5% over baseline
The modified Seattle criteria [5] require presentation of the clinical
features of VOD before day 20 post-SCT.
158 Biol Blood Marrow Transplant 16:157-168, 2010J. A. Coppell et al.VOD is thought to be caused by damage to sinu-
soidal endothelial cells and hepatocytes in zone 3 of
the liver acinus, the area surrounding the central veins.
Sinusoidal obstruction is prominent, leading to pro-
posals for an alternate or complementary terminology
of sinusoidal obstruction syndrome (SOS) [4,8,9].
However this has not been universally adopted; thus
the acronym ‘‘VOD (SOS)’’ is used to both reflect
this debate and provide some consensus [10]. The
pathogenesis is complex, involving cytokine release,
endothelial injury, hemostatic activation, and hepatic
drug detoxification through the glutathione pathway
[3,11,12]. Hepatocellular necrosis, fibrosis, and vascu-
lar occlusion ultimately lead to liver failure, hepatore-
nal syndrome, MOF, and death.
The first case reports describing VOD as a direct
complication of SCT appeared in 1979 [13,14]. Since
then, numerous retrospective and prospective studies
have been performed to determine the incidence of
VOD, define risk factors, and assess the efficacy of pro-
phylactic and treatment modalities. Two separate
groups in the United States have proposed clinical cri-
teria for the diagnosis of VOD in SCT recipients to
preclude the need for histological confirmation of
the disease (Table 1) [4,6].
In addition, prognostic classification (ie, mild,
moderate, or severe) has been frequently quoted in
the literature and in retrospective studies, primarily
based on outcome [5]. As a tool for estimating progno-
sis, Cox regression analysis was used by Bearman et al.
[7] to generate risk curves predictive of severe VOD
derived from a large cohort of patients from the Seattle
Transplant Registry. The investigators evaluated VOD
occurring after the use of 1 of 3 specific chemother-
apeutic regimens: cyclophosphamide and total body
irradiation (TBI), busulphan and cyclophosphamide,
or cyclophosphamide, BCNU, and VP-16. In this
study severe VOD was associated with a case fatality
rate of 98% by day 1100 after SCT. Calculations
based on total serum bilirubin and percentage
weight gain at various time points subsequent to
SCT, up to day 116 [7]. Similar models have not
been proposed for other temporal or therapeutic set-
tings, and models based on potential surrogates (eg,
cytokines, endothelial stress products, markers of fi-
brosis) have yet to be fully defined [15]. Moreover,
whereas there has been general agreement on the
use of clinical criteria for diagnosing VOD, no de-
finitive consensus has been reached on a suitable
classification of severity of the disease, due to the
limitations of existing methods [16-18].
This review analyzes data from the published liter-
ature, including a recent survey exploring the role of
defibrotide in treating severe VOD/MOF as part of
a randomized Phase II dose-finding trial [19,20]. The
objectives were to (1) define the incidence of VOD af-
ter SCT and examine how this has changed over timewith increased sophistication of SCT procedures; (2)
explain the wide variation in VOD incidence reported
in the literature; (3) identify the most commonly used
classifications for ‘‘severe’’ VOD and discuss the limi-
tations of these methods; (4) identify factors with pre-
dictive value for the evolution of severe disease, such as
the development of MOF; and (5) determine expected
outcomes for patients with severe VOD or with VOD
with MOF when only supportive care is available.METHODS
Clinical literaturewas accessed through thePubMed
database using the search terms ‘‘veno-occlusive disease’’
(and variations on this term), ‘‘incidence,’’ ‘‘stem cell
transplantation’’ (and variations), ‘‘bone marrow trans-
plantation (and variations), and ‘‘multiorgan failure’’
(and variations). Records from 1979 to October 2007
were included. A separateMedline search and bibliogra-
phies fromarticles obtainedby both searchmethods also
were examined for references not included in the data-
base searches. A total of 387 citations were recovered;
of these, 149 relevant articles (full tabular listing avail-
able from the corresponding author on request) were
selected for detailed examination and analysis by 2 re-
viewers independently, using the inclusion and exclusion
criteria outlined below. Where several articles reported
on the same cohort of patients, the studies were consid-
ered as a single report to avoid duplication of data in the
analysis (11 studies arranged into 4 groups). Of the final
set of 142 studies, the incidence of VOD in the study
group was reported in 135. The remaining 7 studies
had missing or incomplete data for overall incidence of
VOD but nonetheless were included in the review
because they contained specific information on the
incidence of and mortality from severe VOD.
Our analysis includes all retrospective data analy-
ses, prospective cohort studies, and clinical trials ad-
dressing the incidence of VOD, as well as the degree
of severity of VOD after SCT, published between
1979 and October 2007. For studies comparing pa-
rameters in subgroups of patients (eg, variations in
conditioning regimens with standard conditioning),
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investigating VOD prophylaxis, incidence and out-
come data from historical or contemporary controls
only (when available) were considered; however, ad-
ministration of heparin or ursodiol prophylaxis for
VOD during SCT may not have been clearly docu-
mented if it was not relevant to the theme of the article.
Data are conflicting on the efficacy of heparin or urso-
diol prophylaxis in VOD; although authors have re-
ported a possible beneficial effect [21-25], most
studies (including the large multicenter European
Group for Blood and Marrow Transplantation
[EBMT] study of more than 1600 SCT recipients)
have found neither form of prophylaxis to be effective
in reducing the incidence of VOD [2,16,26-30].
Therefore, rather than exclude such studies from the
analysis, the overall incidence of VOD was used, mak-
ing it impossible to distinguish between patients re-
ceiving or not receiving prophylaxis with heparin or
ursodiol.
Of the 347 citations recovered, 198 were excluded
from the final analysis based on criteria applied in the
following chronological sequence: in vitro or animal
studies (n5 1), studies in languages other than English
(n5 30; some of these were revised and published in
English-language journals), review articles (n5 41),
and studies including\50 subjects (n5 93). VOD is
a rare disease with reported incidences as low as 0%;
thus, studies including\50 SCT recipients were un-
likely to yield statistically significant data on the inci-
dence of and outcome from VOD. Studies in which
prophylactic defibrotide was administered were ex-
cluded (n5 8). The remaining exclusions (n5 25)
were a mixture of case reports, case-control studies,
and other studies where the incidence of or outcome
from VOD could not be determined from the text.
To validate this analysis of outcome from severe
VOD reported in the literature, we also have presented
historical control data from a recent survey conducted
by our multicenter study group that explored the role
of defibrotide for the treatment of severe VOD/MOF
as part of a randomized Phase II dose-finding trial
[19,20]. These data were not included in themain anal-
ysis, but serve to illustrate that severity criteria based
on the evolution of MOF compare favorably with ex-
isting severity criteria and are predictive of VOD out-
come. For this survey, retrospective data were
collected at 3 of the participating centers (City of
Hope National Medical Center, Memorial Sloan Ket-
tering Cancer Center, and M.D. Anderson Cancer
Center). Data were collected for 38 patients, all of
whom had severe VOD as defined by the study criteria
during the 5 years before Institutional Review Board
approval of the study at each site. Eligible patients
(adult and pediatric) met the Baltimore criteria
(Table 1) by day 121 post-SCT and were diagnosed
with encephalopathy and/or renal dysfunction and/orpulmonary dysfunction by day128. Exclusion criteria
included preexisting cirrhosis, viral hepatitis, and
graft-versus-host disease involving the liver or gut,
clinically significant bleeding, inability to maintain
blood pressure except with multiple vasopressors,
and treatment with defibrotide. Complete response
was defined by complete resolution of the signs and
symptoms of VOD after provision of the best available
care. Outcome data for survival at day1100 post-SCT
were collected and reviewed centrally at the Dana-
Farber Cancer Institute.
Statistical Methods
A comprehensive data analysis was performed
using the following a priori techniques modeled on
a meta-analytic approach. Elementary descriptive sta-
tistics for the overall incidence of VOD in the articles
reviewed were expressed as frequency, percentage,
mean (plus 95% confidence interval [CI]), minimum,
maximum, and median values. The 95% CIs were
calculated according to the method of Gardner and
Altman [31]; for smaller samples, a more complex
method for calculating 95% CIs described by Armit-
age and Berry [32], was used. These statistical param-
eters were calculated for the complete set of 135
articles reporting incidence data, as well on selected
subsets of articles as defined by the selection criteria
(eg, type of transplant, VOD criteria used for the diag-
nosis) (Table 2 and Figure 1). Where both the Balti-
more and the Seattle criteria were applied to define
the incidence of VOD in the same population of pa-
tients, only the incidence according to the more com-
monly used Seattle criteria was included in the
statistical analysis. Survival data for the defibrotide
study group were analyzed using c2 and Kaplan-Meier
tests.RESULTS
A total of 135 reports of VOD occurring in popu-
lations of.50 SCT patients were included in this anal-
ysis. (A full tabular listing is available in the
supplement.) In these 135 studies, out of a total of
24,920 SCT recipients, 3425 developed VOD. The
mean incidence of VOD was 13.7% (95% CI,
13.3%-14.1%), with absolute values ranging from
0 to 62.3% (Table 2 and Figure 1). However in thema-
jority of studies (130/135), the variation in incidence
was much smaller than this, ranging from 0 to 40%.
Only 5 studies reported an incidence of VOD
.40%; all of these studies included high-risk patient
groups [5,33-36].
There were marked differences among studies de-
pending on the criteria used for diagnosis and the type
of transplant performed (Table 2 and Figure 1). Using
the Seattle criteria, the mean incidence of VOD was
Table 2. Descriptive Statistics for VOD Incidence from 135 Publications
Group Number of Studies
Total Number
of Patients
Number of Patients
with VOD Mean Incidence, % 95% CI
Min,
%
Max,
%
Median,
%
1. All patients 135 24,920 3425 13.7% 13.3-14.1 0 62.3 13.3
2. Baltimore 33 5261 503 9.6% 8.8-10.4 0 28.9 8.6
3. Seattle 78 14,798 2565 17.3% 16.7-17.9 0 62.3 17.0
4. Auto-SCT 19 3967 344 8.7%* 7.8-9.4 1.5 44.1 6.2
5. Allo-SCT 67 11,285 1453 12.9%* 12.3-13.5 0 62.3 12.0
6. Pre-1994 50 10,943 1260 11.5† 10.9-12.1 1 62.3 9.3
7. Post-1994 74 12,234 1805 14.6† 14.0-15.2 0 53.3 15.4
*P < .001.
†P < .05.
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Figure 1. Graphical representation of the data presented in Table 1.
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whereas with the Baltimore criteria, the mean inci-
dence was 9.6% (95% CI, 8.8%-10.4%; range,
0-28.9%), reflecting the increased stringency of the
Baltimore criteria for diagnosing VOD. In 24 studies,
the criteria used were not specified. The mean inci-
dence of VODwas lower in studies that specifically re-
ported data on autologous SCT recipients compared
with those specifically reporting on allogeneic SCT
(8.7% [95% CI, 7.8%-9.4%] vs 12.9% [95% CI,
12.3%-13.5%]; P\ .001). The incidence range also
was much narrower in studies reporting data on autol-
ogous SCT (0-12% in 13/18 studies vs 0-40% for
allogeneic SCT in 53/57 studies). The 5 studies that
reported an incidence exceeding 12% after autologous
SCT were performed in high-risk patient groups
[37-41].
A subanalysis of the data was undertaken to com-
pare themean incidence of VOD across studies report-
ing on patients undergoing transplantation before and
after 1994, to assess the impact of high-resolution
HLAmatching and other technological advances since
that time, such as the use of less hepatotoxic condition-
ing regimes [2,42]. Surprisingly, the incidence of VOD
calculated across 50 out of 135 studies reporting on
10,943 patients who underwent SCT before 1994
was only 11.5% (95% CI, 10.9%-12.1%), compared
with 14.6% (95%CI, 14.0%-15.2%) in 74 of 135 stud-
ies (12,324 patients) who underwent SCT after 1994
(P#.05). The timing of SCT was not clearly reported
in the remaining 11/135 studies, and these were
excluded from this calculation.
The incidence of severe VOD was specifically re-
ported in 42 studies, in which it ranged from 0 to
77% of all cases of VOD. In 14 of these 42 studies,
the method used to classify severity of VOD was not
reported [24,43-55]. In studies that did specify which
method was used, the most common classification
(23/42 articles) was the retrospective system proposed
by the Seattle group [2,5,16,22,34,36,39,40,56-70]. In
this classification system, patients with mild disease
demonstrate no apparent adverse effects of liver dis-
ease, require no medications for diuresis of excessive
fluid or for hepatic pain, and have completely revers-ible signs, symptoms, and laboratory abnormalities.
Patients with moderate disease experience adverse ef-
fects from liver disease, require sodium restriction
and diuretics to minimize signs of fluid excess (eg,
edema) or medication to alleviate pain from hepato-
megaly, and eventually demonstrate complete resolu-
tion of all signs of liver damage (ie, return of weight
to baseline, decrease in liver size, and decrease in total
serum bilirubin to\34.2 mmol/L [2 mg/dL]). In se-
vere VOD, patients demonstrate adverse effects from
liver disease; signs, symptoms, and laboratory values
do not resolve before day 1100; or death occurs [5].
Only 2 of the 42 studies used the Bearmanmodel alone
[35,71], and another 2 studies used a combination of
the Bearman model and retrospective Seattle classifi-
cation [72,73]. Severe VOD also was classified based
on the presence ofMOF in combination with the Bear-
man criteria in studies by Wadleigh et al. [71] and
Bajwa et al. [74], and based on MOF combined with
the retrospective criteria in studies by Cesaro et al.
[67], Sucak et al. [75], and Haussman et al. [76]. In
these studies, MOF was defined as an oxygen require-
ment (oxygen saturation #90% in room air and/or
ventilator dependence) and/or renal dysfunction (de-
fined as a doubling of baseline creatinine and/or dialy-
sis dependence) and/or encephalopathy, in addition to
liver failure [77].
The mortality rate in patients with severe VOD
was specifically documented in 19 studies
Table 3. Historical Patients with Severe VOD: CR
and Mortality Correlation at Day +100 Post-SCT (n5 38)
Number of Patients Survived to Day +100
Patients with CR 4/38 (11%) 4/4 (100%)
Nonresponders 34/38 (89%) 4/34 (12%)
Biol Blood Marrow Transplant 16:157-168, 2010 161Hepatic Veno-Occlusive Disease after SCT[2,5,36,40,43,45,46,50,55,56,59,62,63,70,72,76,78-80].
The overall mortality from severe VOD across all 19
of these studies was 84.3% (198/235 patients; 95%
CI, 79.6%-88.9%). Fifteen of the 19 studies reported
a mortality rate exceeding 75% when only supportive
treatment was available [2,5,36,40,45,50,55,59,62,63,
70,72,76,78,80]. In 12 of the 19 studies, only limited in-
formation on the cause of death in patients with severe
VODwas provided, but in the other 7, death from severe
VOD was commonly associated with the development
of MOF [5,40,45,50,56,76,78,80]. The correlation be-
tween severe VOD with MOF and high mortality was
further validated by comparison with the defibrotide
study group data [19,20]. This survey revealed a day
1100 mortality of 79%, with 8 of 38 patients alive at
this time point. Analysis by the c2 test demonstrated
a strong statistical association between complete re-
sponse and day1100 survival (P\.0001), with a kappa
coefficient of 0.885 (95% CI, 0.808-0.962), as also re-
flected by a 88% day 1100 mortality in the nonre-
sponders (Table 3 and Figure 2).Figure 2. Kaplan-Meier survival curve for retrospective historical con-
trols with severe VOD (MOF) (n5 38).DISCUSSION
An early prospective study to determine the inci-
dence of VOD associated with SCT reviewed 255
consecutive patients undergoing bone marrow trans-
plantation for malignancy between 1978 and 1980
[4]. Fifty-three patients (21%) met the Seattle criteria
for the diagnosis of VOD (Table 1). The accuracy of
these criteria was demonstrated by comparing this
data with histological findings in a cohort of 64 patents
who underwent biopsy or autopsy.
Jones et al. [6] retrospectively evaluated 235
consecutive patients who underwent bone marrow
transplantationbetween1982and1985.Histological di-
agnosis performed in a subsection of patients was found
to correlatewellwith thepresenceof a consistent clinical
syndrome of liver dysfunction occurring within the first
3 weeks after marrow infusion. The incidence of VOD
using the Baltimore or Jones criteria was 22% (52/
235), which was comparable with the Seattle series [4]
(Table 1).
The conclusion from both the original Seattle and
Baltimore series was that VOD has a specific clinical
presentation, which enables diagnosis without the
need for liver biopsy. Both criteria are commonly
used in clinical practice, but the Seattle criteria are
quoted more frequently in the literature for defining
the incidence of VOD among SCT recipients.
The largest multicenter prospective study to ad-
dress incidence of VOD among SCT recipients was
published in 1998 by the EBMT [2]. In that study,
1652 consecutive BMT patients were evaluated over
a 6-month period in 73 participating EBMT centers
for the occurrence of VOD according to Baltimorecriteria. VOD was diagnosed in 87 patients overall
(incidence, 5.3%; 95% CI, 4.2%-6.4%). There was
a 3-fold difference in incidence between allograft and
autograft recipients (8.9% and 3.1%; respectively;
P\ .0001), representing a significantly increased rela-
tive risk of VOD after allogeneic SCT compared with
autologous SCT.
In some studies, both Baltimore and Seattle criteria
were applied to the same cohort of patients, demon-
strating significant differences in the incidence of
VOD depending on the criteria used [30,65,72,81,82].
This may account for some of the observed variation
inVOD incidence in other studies. By definition, all pa-
tients meeting the Baltimore criteria also satisfy the Se-
attle criteria, but not vice versa. The Baltimore criteria
result in a lower rate of VOD diagnosis and less
variation in the incidence of VOD among studies
(Table 1). The increased stringency of the Baltimore
criteria comes from the requirement for hyperbilirubi-
nemia of.34 mmol/L, comparedwith.27 mmol/L in
the Seattle criteria, and the need for the presence of 2 or
more additional clinical features of VOD, compared
with only one additional feature in the Seattle criteria
(Table 2) [81]. Blostein et al. [81] applied both sets of
criteria to a cohort of 101 SCT recipients and noted
that a larger proportion of patients with VOD diag-
nosed by the Baltimore criteria died from severe disease
at an early stage compared with those diagnosed by the
Seattle criteria. They concluded that the Baltimore
criteria identify more patients at increased risk of poor
outcome.
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differences in study design, including endpoints and
methods of data reporting, contribute to the be-
tween-study variation in VOD incidence. Many stud-
ies rely on retrospective data extraction, which is
highly dependent on the accuracy and extent of docu-
mentation and, to a lesser extent, on the perceptions of
the attending physician [83,84]. The development of
jaundice after SCT often is attributable to multiple
causes, including cholestasis, likely resulting in under-
diagnosis or overdiagnosis of VOD in many cases
[83,84]. Although clinical criteria appear to be ade-
quate for a diagnosis of VOD in the majority of pa-
tients, recent interventional studies have sought to
confirm the diagnosis by histological and other means
in confounding cases [77,85,86].
In the second study published by the Seattle group
in 1993 [5], VOD developed in 190 of 355 patients (in-
cidence, 54%; 95% CI, 48%-59%). The clinical crite-
ria used for that study were similar to those developed
in the 1984 study [4], but with the stipulation that the
clinical features of VOD appear within 20 days of
transplantation (the modified Seattle criteria). Three
additional studies from that group have reported sim-
ilarly high occurrences of VOD [36,58,64]. The in-
creased incidence noted in the more recent reports
compared with the incidence of 21% in the 1984 Seat-
tle study was attributed to increased use of intensive
high-dose conditioning regimens.
Similarly, the lower incidence of VOD reported in
the 1998 EBMT study was thought to be related to the
variable frequency of risk factors, patient selection,
definitions of VOD used by different centers, and ad-
vances in HLA typing of allogeneic grafts since the
1993 Seattle report [47]. This is illustrated by the
fact that the majority of the patients in the Seattle se-
ries received an allogeneic transplant and high-dose
chemotherapy, compared with only 29% of those in
the EBMT study. Indeed, when patients with several
risk factors for VOD in the EBMT study were ana-
lyzed separately, the incidence was similar to that re-
ported in the Seattle series. Other factors that likely
contributed to the lower incidence of VOD reported
in the EBMT and other studies include the widespread
use of BEAM (BCNU, etoposide, cytarabine, and
melphalan) conditioning (a regimen that lacks major
sinusoidal liver toxins) for autologous SCT in Europe,
and the historical administration of lower doses of
TBI in European centers compared with their US
counterparts [87].
In some of the smaller and more recent series
reviewed here, no VODwas reported in the study pop-
ulation [88-90]. This may be due to both small sample
size and improved understanding of the biology of
SCT, allowing modification of transplantation proto-
cols to minimize toxicity. For example, lower inci-
dences of VOD and other transplantation-relatedcomplications have been reported with the use of
reduced-intensity conditioning (RIC) protocols
[88,91], i.v. or targeted busulfan (dose-adjusted ac-
cording to individual patient pharmacokinetics)
[72,92-94], T cell depletion [62,65,88,89,92,95], and
fractionation of the TBI dose used for SCT condition-
ing [96-100]. It is known that fewer SCT complica-
tions arise when HLA-matched siblings are used as
donors [98,101-103], and in the last decade, the advent
of high-resolutionHLA typing has led to a significantly
reduced complication rate and improved outcome for
SCT patients overall [104].
Despite these advances, our current analysis sug-
gests that the overall incidence of VOD has actually in-
creased over time. The reason for this is unclear, but in
some studies specific strategies, such as i.v. dosingofbu-
sulfan in children, havebeen associatedwithmoreVOD
rather than less, suggesting that such measures are not
uniformly protective in all SCT populations [105].
Other contributing factors have included extension of
the age limit for transplantation by more widespread
use of RIC protocols, the use ofmultiple alkylating reg-
imens in certain pediatric populations (eg, neuroblas-
toma), reservation of SCT for patients with relapsed
or resistant disease due to advances in novel remission
induction therapy, introduction of promising but po-
tentially toxic new agents for graft-versus-host disease
prophylaxis (eg, sirolimus, everolimus), second or third
SCT in patients encountering secondary malignancies
after cure of their first, and the increasing use of mis-
matched donors [37,38,104,106-109].
The variation in the reported incidence of VOD is
multifactorial, reflecting differences among studies in
the type of transplant, conditioning regimen, other
drugs received, primary disease, coexisting medical
conditions, risk factors for liver toxicity, study design,
and the criteria used tomake the diagnosis [15,81,110].
Thus, a limitation of our analysis is that the data were
not stratified according to such variables. Conversely,
the strength of the study is the large number of patients
included, whichmade it possible to obtain useful infor-
mation about the overall incidence of VOD among
SCT recipients.
Although the Seattle and Baltimore criteria have
become widely accepted as standards for clinical
diagnosis, there has been less agreement among re-
searchers on a suitable classification for the severity
of VOD [2,16,17]. The classification based on the ret-
rospective assessment of outcome for the cohort of 355
patients in the 1993 Seattle study identified 54 patients
with severe VOD. Although death was not the only re-
quirement for assignment to the severe VOD category
in this study, 53/54 patients (98%) died by day 1100.
This retrospective classification system was used in
the 1998 EBMT study [2]. The incidence of severe
VOD in those patients was 27.6% (24/87), which is
comparable with the incidence in the Seattle cohort
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tients with severe VODwas 100%. Importantly, a simi-
lar incidence of severe VOD by this definition after
allogeneic and autologous SCT has been reported in
several smaller studies [16,22,39,46,58,63,65], but
a much higher incidence of severe VOD (around 50%)
has been reported in allograft recipients [36,47,49,
50,57,62,111]. The large EBMT study reported a 3-
fold higher incidence of VOD in allogeneic SCT recip-
ients (8.9% vs 3.1%; P\ .0001), but did not include
a separate analysis of the incidence of and mortality
from ‘‘severe’’ disease (defined retrospectively) between
autologous and allogeneic SCT patients. Given that al-
logeneic SCT is associated with greater immunologic
and cytokine-mediated disturbances, the incidence of
severe VOD and death would be expected to be higher
in allogeneic SCT recipients, an observation also sup-
ported by more recent studies [77].
A prospective risk-benefit analysis is needed before
any interventional trial using agents with potentially
harmful side effects to treat VOD, such as recombi-
nant tissue plasminogen activator (rtPA) [73,112].
For this purpose, data from the second Seattle cohort
of 355 patients were used to develop a logistic regres-
sion model [7]. This model was found to have a speci-
ficity exceeding 90%, and its accuracy was tested on
a cohort of similarly conditioned patients at the same
center. However this model was specifically developed
to justify a clinical trial of rtPA in VOD, which has the
potential for serious hemorrhagic complications. It ap-
plies only to those patients receiving certain specific
regimens of intensive cytoreductive therapy for hema-
tologicmalignancy [113] and accounts for only the first
16 days post-SCT, which is before VOD develops in
a significant proportion of patients [40,57,114]. De-
spite these limitations, investigators have found this
model to be useful, particularly when the proposed
treatment is associated with serious side effects [73].
Because of the limitations of existing criteria for
evaluating the severity of VOD, the evolution of
MOF in patients with VOD has been suggested as
a more reliable indicator of both severity and outcome
[17,67,71,74-77,113,115,116]. Importantly, the rela-
tionship between severe VOD and MOF was analyzed
in the Seattle cohort study using time-dependent pro-
portional hazards models. MOF was common in pa-
tients with severe VOD compared with patients with
mild or moderate VOD (P\.001) [5]. Similarly, Jones
et al. [6] reported that many patients with VOD died
with MOF in the Baltimore cohort of 235 SCT pa-
tients. More recently, in a cohort study of 199 SCT pa-
tients, Haire and coworkers [117-120] found that the
occurrence of VOD was often predictive of the subse-
quent development of MOF and increased mortality.
A series of other reports have demonstrated that the
development of MOF in patients after SCT is associ-
ated with high mortality (60%-100%) regardless ofthe etiology [121-127]. More specifically, hepatic dys-
function after SCT is often predictive of later MOF
[117-120,128] and greatly reduces the likelihood of
surviving MOF [129]. For instance, elevated bilirubin
is a known risk factor for the development of acute
renal failure (ARF) [130-132]. ARF after SCT rarely
occurs in isolation and usually occurs as part of
MOF including the liver, often manifested as VOD
[40,50,61,128,133]. This association between severe
VOD and ARF has been reported in numerous studies
[5,16,39,62,114,125,133-136], and the combination of
VOD with ARF and/or mechanical ventilation as a re-
sult of pulmonary dysfunction is associated with espe-
cially high mortality, particularly in the pediatric
population [125,126,131,135,137-139].
The Seattle study found that mortality from severe
VOD commonly resulted from progressive MOF and
rarely from liver failure per se [5,140]. Thus, the inves-
tigators concluded that all transplantation-related
causes of death should be considered in the assessment
of outcome in such patients. In support of this, 16/24
patients with severe VOD in the EBMT series died
from VOD (corresponding to 1% of the whole series,
18.4% of VOD patients, and 66.7% of those with se-
vere VOD) [2]. However, the remaining 8 patients
with severe VOD in that report died before day
1100 from a related cause, including sepsis. Thus,
the all-cause mortality at day 1100 was 100%. Jones
et al. [6] also reported high mortality from MOF
with VOD (47%; 24/52) in the Baltimore cohort.
Several other studies also have reported MOF as the
major cause of death in patients with severe VOD
[21,74,141]. Consequently, VOD with MOF has
been used to prospectively define severe VOD in cur-
rent clinical studies of therapy for VOD, such as rtPA
and defibrotide [74-77,113,115,116], and the evolu-
tion of MOF in patients with VOD has become widely
accepted as an indication of severity and a predictor of
poor outcome [17,67,71,74,76,77,113,115,116].
It is noteworthy that the exploratory historical con-
trols in the survey performed by the defibrotide study
group demonstrate a mortality rate of 79% at day
1100, which is similar to the 84.3% mortality esti-
mated from the other studies reviewed here. Notable
exceptions in the literature analysis included a multi-
center study based in Philadelphia that reported amor-
tality of only 30% in patients with severe VOD [5,56],
and a study byVassal et al. [46] in which themethod for
determining severity was not defined. These outliers
highlight an additional problem with interpreting the
retrospective severity criteria: what constitutes ‘‘reso-
lution of the symptoms and signs of liver disease by
day 1100’’? Minor elevations in bilirubin or serum
transaminase concentration are common after SCT
and are often due to the effects of drugs, such as cyclo-
sporin. A recent publication reported a correlation
between increasing serum bilirubin value in VOD
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increase in mortality for a given increase in bilirubin
value is greater when the starting value was lower
[142]. This suggests that patients with a high bilirubin
level at presentation that remains stable are less likely to
die than patients with a low bilirubin level that rises
rapidly. Therefore, the retrospective evaluation of se-
verity of VOD can be subjective, may result in errone-
ous classification, and has poor predictive value for
outcome. We propose that classification of VOD se-
verity should include concurrent organ dysfunction in
at least one other system (eg, renal failure) to fulfill a re-
quirement for MOF, and as such should be universally
accepted by the transplantation community as the de-
finitive replacement for previous classification systems.
In summary, despite recent advances, such as mo-
lecular HLA typing and the use of less-toxic SCT pro-
tocols, a small but significant increase in the mean
incidence of VOD over time is reported in the pub-
lished literature. The overall incidence of VOD is
much lower than was indicated in early reports. How-
ever, the combination of clinical criteria with diagnos-
tic tests, facilitated by advances in our understanding
of the histopathology underlying VOD, should lead
to increased diagnostic accuracy in confounding cases
and thus reduce variation between future studies.
Severe VOD is associated with a mortality rate
.80% on day 1100 post-SCT based on our analysis,
and is most frequently associated with hepatorenal syn-
drome andprogression toMOF.The evolution ofMOF
in patients with VOD has become widely accepted as
a reliable and clinically useful indicator of severity and
outcome of VOD, and our analysis supports this view.
Future research directions will include large sur-
veys of current SCT databases for incidence and out-
come. Given that more innovative approaches to
treatment of this disease are required, prospective
studies of promising therapeutic and prophylactic in-
terventions should be used as a platform to validate
clinical features, prediction of outcome, and surrogate
markers of severe VOD.ACKNOWLEDGMENTS
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